

## Key References for VCCEP p-Dioxane Report

Argus MF, Arcos JC *et al.*, (1965). Studies on the carcinogenic activity of the protein-denaturing agents: hepatocarcinogenicity of dioxane. *J Natl Canc Inst.* 35:949-958.

Argus MF, Sohal RS *et al.*, (1973). Dose-response and ultrastructural alterations in dioxane carcinogenesis. *Europ. J. Cancer.* 9:237-243.

Buffler PA, Wood SM, Suarez L, and Kilian DJ. (1978). Mortality follow-up of workers exposed to 1,4-dioxane. *J. Occup. Med.* 20:255-259.

CalEPA (California Environmental Protection Agency). (2000). 1,4-Dioxane: Chronic Toxicity Summary. Office of Environmental Health Hazard Assessment, California.

DeRosa, C., Wilbur, S *et al.* (1996). Health evaluation of 1,4-dioxane. *Toxicol Ind Health.* 12:1-43.

Dietz FK, Stott WT *et al.*, (1982). Nonlinear pharmacokinetics and their impact on toxicology: illustrated with dioxane. *Drug Metab Rev.* 13:963-981.

ECETOC (European Chemical Industry Ecology and Toxicology Centre). (1983). Joint assessment of commodity chemicals - no.2: 1,4-dioxane. Brussels, Belgium.

Giavini E, Vismara C *et al.*, (1985). Teratogenesis study of dioxane in rats. *Toxicol Lett*, 26:85-88.

Goldsworthy TL, Monticello TM *et al.*, (1991). Examination of potential mechanisms of carcinogenicity of 1,4-dioxane in rat nasal epithelial cells and hepatocytes. *Arch Toxicol.* 65:1-9.

Hartung R. (1989). Health and environmental effects assessment for 1,4-dioxane. Gelman Sciences Inc. Michigan., USA.

HSDB (Hazardous Substance Data Bank). (2007). 1,4-Dioxane summary. MEDLARS online information retrieval system, National Library of Medicine, USA.

Kociba RJ, McCollister SB *et al.*, (1974). 1,4-Dioxane. I. results of a 2-year ingestion study in rats. *Toxicol Appl Pharmacol.* 30:275-286.

Kociba RJ, Torkelson TR *et al.*, (1975). 1,4-Dioxane: correlation of the results of chronic ingestion and inhalation studies with its dose-dependent fate in rat. *Proceedings of the 6<sup>th</sup> Annual Conference on Environmental Toxicology*, **21**(22): 345-354.

Leung H and Paustenbach DJ. (1990). Cancer risk assessment for dioxane based upon a physiologically based pharmacokinetic approach. *Toxicol Lett* 51: 147-162.

NCI (National Cancer Institute). (1978). Bioassay of 1,4-dioxane for possible carcinogenicity. National Cancer Institute, PB-285 711. Department of Health, Education and Welfare. DHEW publication no. (NIH) 78-1330.

NICNAS (National Industrial Chemicals Notification and Assessment). (1998). 1,4-Dioxane: Priority Existing Chemical No. 7. Commonwealth of Australia. Sydney.

NIOSH (National Institute for Occupational Safety and Health). (1977). Occupational exposure to dioxane: criteria for an occupational standard. DHEW Publication No 77-226, Cincinnati, Ohio, NIOSH, pp 193.

Reitz, RH, McCroskey, PS *et al.*, (1990). Development of a physiologically based pharmacokinetic model for risk assessment with 1,4-dioxane. *Toxicol Appl Pharmacol.* 105:37-54.

Stickney JA, Sager SL, Clarkson JR, Smith LA, Locey BJ, Bock MJ, Hartung R, and Olp SF. (2003). An updated evaluation of the carcinogenic potential of 1,4-dioxane. *Reg Toxicol Pharmacol* 38(2):183-195.

Stott WT, Quast, JF *et al.*, (1981). Differentiation of the mechanism of oncogenicity of 1,4-dioxane and 1,3-hexachlorobutadiene in the rat. *Toxicol. Appl. Pharmacol.* 60:287-300.

Stott WT and Watanabe PG. (1982). Differentiation of genetic versus epigenetic mechanisms of toxicity and its application to risk assessment. *Drug Metab Rev* 13: 853-857.

Stott WT. (1988). Chemically produced proliferation of peroxisomes: Implications for risk assessment. *Regul Toxicol Pharmacol* 8: 125-159.

Stott WT, Young JT, Calhoun LL, and Battjes JE. (1988). Subchronic toxicity of inhaled technical grade 1,3-dichloropropane in rats and mice. *Fundam Appl Toxicol* 11: 207-220.

Thiess AM *et al.*, (1976). Results of occupation-medical investigations of workers exposed to dioxane. *Arbeitsmed. Socialmed. Praeventivmed.* 11:36-46.

TNO (The Netherlands Organization for Applied Scientific Research) and National Institute for Public Health and the Environment (RIVM). (2002). European Union Risk Assessment Report: 1,4-Dioxane. European Chemicals Bureau, European Commission.

Torkelson TR, Leong BKJ *et al.*, (1974). 1,4-Dioxane. II. results of a 2-year inhalation study in rats. *Toxicol Appl Pharmacol.* 30:287-298.

USEPA. (1997). Exposure Factors Handbook. Environmental Protection Agency. Washington DC. EPA/600/C-99/001.

USEPA. (2006). Child-Specific Exposure Factors Handbook. External review draft. Environmental Protection Agency. EPA-600/R06/096A.

Yamazaki K, Ohno H, *et al.*, (1994). Two-year toxicological and carcinogenesis studies of 1, 4-dioxane in F344 rats and BDF1 mice. Proceedings of the Second Asia-Pacific Symposium on Environmental and Occupational Health, 22-24 July, 1993 Kobe. pp 193-198.

Young JD, Braun, WH *et al.*, (1976). Short communication. 1,4-Dioxane and beta-hydroxyethoxyacetic acid excretion in urine of humans exposed to dioxane vapors. Toxicol Appl Pharmacol. 38:643-646.

Young JD, Braun, WH *et al.*, (1977). Pharmacokinetics of 1,4-dioxane in humans. J. Toxicol Environ Health 3:507-520.

Young JD, Braun WH *et al.*, (1978a). Dose-dependent fate of 1,4-dioxane in rats. J Toxicol Environ Health. 4:709-726.

Young JD, Braun WH *et al.*, (1978b). The dose-dependent fate of 1,4-dioxane in rats. J. Environ. Path. Toxicol. 2:263-282.